Antidepressants: Current strategies and future opportunities

Current Pharmaceutical Design

Volumn 16, Issue 38, 2010, Pages 4243-4253

  Uppal, Archana ^a   Singh, Anita ^b   Gahtori, Prashant ^b   Ghosh, Surajit Kumar ^c   Ahmad, Mohammad Zaki ^d  

^a Shri Guru Ram Rai University   (India)

^b Devsthali Vidyapeeth College of Pharmacy Lalpur   (India)

^c DIBRUGARH UNIVERSITY   (India)

^d Dreamz College of Pharmacy   (India)

Author keywords

Depression; GABA; Glutamate; Monoamine; Serotonin; SSRIs

Indexed keywords

1 (3,4 DICHLOROPHENYL) 3 AZABICYCLO[3.1.0]HEXANE; 1 [1 (4 CHLOROPHENYL)CYCLOBUTYL] 3 METHYLBUTANAMINE; 3 (3,4 DICHLOROPHENYL) 2 (METHOXYMETHYL) 8 AZABICYCLO[3.2.1]OCTANE; ANTIDEPRESSANT AGENT; AZ 6765; FLUOXETINE; GLUTAMIC ACID; GW 23296; JNJ 18038683; LOSMAPIMOD; LUAA 21004; LUAA 24530; LY 2216684; MELANIN CONCENTRATING HORMONE RECEPTOR 1; MELANIN CONCENTRATING HORMONE RECEPTOR 1 ANTAGONIST; MELANOCORTIN RECEPTOR AGONIST; MONOAMINE OXIDASE INHIBITOR; N METHYL DEXTRO ASPARTIC ACID; NORADRENALIN UPTAKE INHIBITOR; ONO 2333M; ORG 3417; ORG 34850; ORVEPITANT; PEXACERFONT; SEROTONIN 1A AGONIST; SEROTONIN 1A ANTAGONIST; SEROTONIN 2C AGONIST; SEROTONIN 2C ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; TC 5214; TRICYCLIC ANTIDEPRESSANT AGENT; TYRIMA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VABICASERIN; VASOPRESSIN RECEPTOR ANTAGONIST; VILAZODONE;

ANXIETY; ANXIETY DISORDER; ARTICLE; COGNITIVE DEFECT; CONSTIPATION; DEPRESSION; DROWSINESS; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; FATIGUE; GASTROINTESTINAL SYMPTOM; HEART ARRHYTHMIA; HEART BEAT; HUMAN; MEDICAL RESEARCH; MEMORY DISORDER; MICTURITION DISORDER; MUSCLE TWITCH; NAUSEA; NONHUMAN; PEPTIDERGIC NERVOUS SYSTEM; PHARMACEUTICAL CARE; PRIORITY JOURNAL; RESTLESSNESS; SEXUAL DYSFUNCTION; SIDE EFFECT; SLEEP DISORDER; SWEATING; URINE RETENTION; WEAKNESS; WEIGHT GAIN; XEROSTOMIA;

ANIMALS; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; HUMANS;

EID: 79951719299     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210794519110     Document Type: Article

References (94)

1. World Health Organization Programs and Projects, Mental health, Disorder management. Available from: http: //www.who.int/mental_health/management/depression/definition/e n
2. Zaengel T, Thelen E, Thijs J. Perspectives in personal healthcare. In: Spekowius G, Wendler T, Eds. Advances in health care technology care shaping the future of medical. Netherlands: Springer 2006; vol. 6(6): pp. 439-462.
3. Oliffe J, Men PM. Depression and masculinities: A review and recommendations. J Men's Health 2008; 5(3): 194-202.
4. Potter WJ. Antidepressant agents. In: Katzung BG, Basic and clinical Pharmacology, 10th ed. USA: Mcgraw Hill companies 2007; pp. 475-79.
5. Lehtinen V, Joukamaa M. Epidemiology of depression: Prevalence, risk factors and treatment situation. Acta Psychiatr Scand 1994; 89(377): 7 -10.
6. Karel MJ, Hinrichsen G. Treatment of depression in late life: Psychotherapeutic interventions. Clin Psychol Rev 2000; 20(6): 707-29.
7. Raz A. Perspectives on the efficacy of antidepressants for child and adolescent depression. PLoS Med 2006; 3(1): 9.
8. Kennard A. Relapse and Recurrence in Pediatric Depression. Child Adolesc Psychiatr Clin North Am 2006; 15(4): 1057-1079.
9. Rockville M. Treatment of depression - newer pharmacotherapies evidence report 2005, 7.
10. Phillipsa KA, Hollander E. Treating body dysmorphic disorder with medication: Evidence, misconceptions, and a suggested approach. Body Image 2008; 5(1): 13-27.
11. Richard IH. Depression in Parkinson's disease: current treatment options. Neurology 2000; 2(3): 263-73.
12. Perry PJ, Wehring HJ, Alexander B, Liskow B. Clinical psychopharmacology and other somatic therapies. In: Fatemi SH, Clayton, JP, Eds. The medical basis of psychiatry, 3rd ed. USA: Totowa Humana Press 2008; pp. 577-634.
13. Milla M. Dual- and triple-acting agents for treating core and comorbid symptoms of major depression: novel concepts and new drugs. Neurotherapeutics 2009; 6: 53-77.
14. Pacher P, Kecskemeti VV. Trends in the development of new antidepressants. Is there a light at the end of the tunnel. Curr Med Chem 2004; 11(7): 925-43.
15. United States: Federal Government, Department of Veterans Affairs Available from: http: //clinicaltrials.gov/ct2/show/ NCT00018733
16. Mosholder AD, Willy M. Suicidal adverse events in pediatric randomized, controlled clinical trials of antidepressant drugs are associated with active drug treatment: a meta-analysis. J Child Adolesc Psychopharmacol 2006; 16(1-2): 25-32.
17. Gareri P, Falconi U, Fazio PD, Sarro GD. Conventional and new antidepressant drugs in the elderly. Progr Neurobiol 2000; 61 (4): 353-96.
18. Leigh H, Streltzer J. Handbook of Consultation-Liaison Psychiatry. 3rd ed. In: Singh K, Skotzko C, Ochitill H. Immune-compromised patients: human immunodeficiency virus and organ transplantation. US: Springer 2007; pp. 221-247.
19. Martin E, Ressler K, Binder E, Nemeroff C. The Neurobiology of Anxiety Disorders: Brain Imaging, Genetics, and Psychoneuroendocrinology. Psychiatr Clin North Am 2009; 32(3): 549-75.
20. Lewi PJ, Colpaert FC. On the classification of antidepressant drugs. Psychopharmacology 1976; 49(2): 119-224.
21. Baldessarini RJ. Drugs and the treatment of Psychiatric Disorder. 10th ed. In: Hardman JG, Limbird LE, Gilman AG, Eds. Goodman and Gilman's: The Pharmacological Basis of Therapeutics., New York: McGraw-Hills 2001; pp. 452-53.
22. Singh AN. Recent advances in the psychopharmacology of psychosomatic medicine. Int Congr Ser 2006; 1287: 206-212.
23. Sussman N, Stahl S. Update in the pharmacotherapy of depression. Am J Med 1996; 101(6): 26S-36S.
24. Pacher P, Ungvari Z, Kecskemeti V, Furst S. Review of cardiovascular effects of fluoxetine, a selective serotonin reuptake inhibitor, compared to tricyclic antidepressants. Curr Med Chem 1998; 5: 381-90.
25. Burgess CD. Effects of antidepressants on cardiac function. Acta Psychiatr Scand 2007; 63(290): 370-9.
26. Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin GR. International Union of Pharmacology classification of receptors for 5- hydroxytryptamine (Serotonin). Pharmacol Rev 1994; 46: 157-203.
27. Barnes NM, Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology 1999; 38: 1083-152.
28. Schechter LE, Ring RH, Beyer CE, et al. Innovative Approaches for the Development of Antidepressant Drugs: Current and Future Strategies. NeuroRx 2005; 2(4): 590-611.
29. Artigas F, Romero L, Montigny C, Blier P. Acceleration of the effect of selected antidepressant drugs in major depression by 5- HT1A antagonists. Trends Neurosci 1996; 19: 378-83.
30. Dawson LA, Nguyen HQ, Smith DL, Schechter LE. Effect of chronic fluoxetine and WAY-100635 treatment on serotonergic neurotransmission in the frontal cortex. J Psychopharmacol 2002; 16: 145-52.
31. Kreiss DS, Lucki I. Effects of acute and repeated administration of antidepressant drugs on extracellular levels of 5-hydroxytryptamine measured in vivo. J Pharmacol Exp Ther 1995; 274: 866-76.
32. Jacobson LH, Cryan JF. Feeling strained: influence of genetic background on depression-related behavior in mice: a review. J Behav Genet 2007; 37(1): 171-213.
33. Romero L, Hervas I, Artigas F. The 5-HT1A antagonist WAY-100635 selectively potentiates the presynaptic effects of serotonergic antidepressants in rat brain. Neurosci Lett 1996; 219: 123-26.
34. Romero L, Artigas F. Preferential potentiation of the effects of serotonin uptake inhibitors by 5HT1A receptor antagonist in the dorsal raphe pathway: role of somatodendritic autoreceptor. J Neurochem 1997; 68: 2593-603.
35. Forster EA, Cliffe IA, Bill DJ, Dover GM, Jones D, Reilly YA. Pharmacological profile of the selective 5 HTa receptor antagonist WAY-100635. Eur J Pharmacol 1995; 281: 81-88.
36. Kung MP, Zhuang ZP, Frederick D, Kung HF. In vivo binding of [1231]-4(2'methoxy phenyl-1- [2'-N-2''pyridinyl)-p-iodobenzamido] ethyl-piperazine p-MPPI, to 5HT1A receptors in rat brain. Synapse 1994; 8: 359-66.
37. Mos J, Van Hest A, Van Drimmelen M, Herremans AH, Olivier B. The putative 5HT1A receptor antagonist DU125530 blocks the dis criminative stimulus of the 5HT1A receptor agonist flesinoxan in pigeon. Eur J Pharmacol 1997; 325: 45-53.
38. Johansson L, Sohn D, Thorberg SO, Jackson DM, Kelder D, Larsson LG. The pharmacological characterization of novel selective 5- hydroxytryptamine1A receptor antagonist. J Pharmacol Exp Ther 1997; 283: 216-25.
39. Rozas I. Improving antidepressant drugs: update on recently patented compounds. Expert Opin Therapeut Pat 2009; 19 (6): 827-845.
40. Klint T, Weikop P. Monoamine transporters as continuing targets for drug discovery in depression. Drug Discov Today: Therap Strat 2004; 1(1): 111-116.
41. Sitte HH, Freissmuth M. Handbook of Experimental Pharmacology. In: Lesch KP, Mössner R, Eds. Inactivation of 5HT Transport in Mice: Modeling Altered 5HT Homeostasis Implicated in Emotional Dysfunction, Affective Disorders, and Somatic Syndromes. Heidelberg: Springer Berlin 2006; 175: 417-456.
42. Cremers TIF, Wilkstroem HW, Den BJA, et al. The combination of a serotonin reuptake inhibitor and a 5-HT2C antagonist, inverse agonist or partial agonist. Eur Pat EP1396267 2004.
43. Takeuchi H, Yatsugi, S, Hatanaka K, Nakato K, Hattori H, Sonoda R. Pharmacological studies on YM992, a novel antidepressant with selective serotonin reuptake inhibitory and 5HT2A receptor antagonistic activity. Eur J Pharmacol 1997; 329: 27-35.
44. Hatanaka K, Nomura T, Hidaka K, Takeuchi H, Yatsugi S, Fujii, T. Biochemical profile of YM992, a novel selective serotonin reuptake inhibitor with 5-HT2A receptor antagonist activity. Neuropharmacology 1996; 35: 1621-26.
45. Wood MD, Reavill C, Trail B, Wilson A, Stean T, Kennett GA. SB-243213; a selective 5-HT2C receptor inverse agonist with improved anxiolytic profile: lack of tolerance and withdrawal anxiety. Neuropharmacology 2001; 41: 186-99.
46. Lopez-Rodriguez ML, Ayala D, Benhamu B, Morcillo MJ, Viso A. Arylpiperazines derivatives acting at 5-HT (1A) receptors. Curr Med Chem 2002; 9: 443-69.
47. Wood MD, Thomas DR, Watson JM. Therapeutic potential of serotonin antagonist in depressive disorders. Expert Opin Investig Drugs 2002; 11: 457-67.
48. Foubert GD, Murray TK, ONeill MJ, Zetterström TSC. 5-HT6 receptor-selective upregulation of brain-derived neurotrophic factor mRNA in the rat brain. Fed Eur Neurosci Soc 2004; 11: 57.
49. Schechter LE, Smith DL, Li P, et al. Pharmacological profile of a novel and selective 5-HT6 receptor agonist: WAY-466. The EPHAR Satellite Meeting on Serotonin, Porto, Portugal 2004.
50. Pinder R, Mianserin M. Pharmacological and clinical correlates. Nord J Psychiatry 1991; 45(24): 13-26.
51. Evrard, DA. Recent stratergies for the development of new antidepressant drugs. Ann Report Med Chem 2006; 41: 24-38.
52. Caille D, Bergis OE, Fankhauser C, Gardes A, Adam R, Charieras T. Beflaxatone, a new reversible and selective monoamine oxidase- A inhibitors.II. Pharmacological profile. J Pharmacol Exp Ther 1996; 277: 265-77.
53. Gerardy J., Dress A. Regional action of brofaromine on rat brain MAO-A and MAO-B. Progr Neuro-Psychopharmacol Biol Psychiatry 1998; 22(7): 1141-55.
54. Rosenzweig P, Patat A, Curet O, Durrieu G, Dubruc C, Zieleniuk I. Clinical pharmacology of befloxatone: a brief review. Affect Disord 1998; 5: 305-12.
55. Maes M. The immunoregulatory effects of antidepressants. Hum Psychopharmacol Clin Exp 2001; 16 (1): 95-103.
56. Skolnick P, Popik P, Janowsky A, Beer B, Lippa AS. Antidepressant like actions of DOV 21,947: a "triple" reuptake inhibitor. Eur J Pharmacol 2003; 461: 99-104.
57. Zavitsanoua K, Nguyena V, Newellb K, Ballantynea P, Huang X. E. Rapid cortico-limbic alterations in AMPA receptor densities after administration of PCP: Implications for schizophrenia. J Chem Neuroanat 2008; 36(2): 71-76.
58. Hoang CJ, Hay M. Expression of metabotropic glutamate receptors in nodose ganglia and the nucleus of the solitary tract. Am J Physiol Heart Circ Physiol 2001; 281(1): H457-H62.
59. Chaki S, Okubo T, Sekiguchi Y. Non-monoamine-based approach for the treatment of depression and anxiety disorders. Recent Pat CNS Drug Discov 2006; 1: 1-27.
60. Belozertsevaa IV, Kos T, Popik P, Danysz W, Bespalova AY. Antidepressant like effects of mGluR1 and mGluR5 antagonists in the rat forced swim and the mouse tail suspension tests. Eur Neuropsychopharmacol 2007; 17(3): 172-9.
61. Yoshimizu T, Shimazaki T, Ito A, Chaki S. An mGluR2/3 antagonist, MGS0039, exerts antidepressant and anxiolytic effects in behavioral models in rats. Psychopharmacology 2006; 186(4): 587-93.
62. Nakagawa Y, Sasaki A, Takashima T. The GABAB receptor antagonist CGP36742 improves learned helplessness in rats. Eur J Pharmacol 1999; 381: 1-7.
63. Slattery DA, Desrayaud S, Cryan JF. GABAB receptor antagonistmediated antidepressant like behavior is serotonin dependent. J Pharmacol Exp Ther 2005; 3(12): 290-96.
64. Mombereau C, Kaupmann K, Froestl W, Sansig G, van der Putten H, Cryan JF. Genetic and pharmacological evidence of a role for GABAB receptors in the modulation of anxiety and antidepressant like behavior. Neuropsychopharmacology 2004; 29: 1050-62.
65. Vale W, Spiess J, Rivier C, Rivier J. Characterization of a 41- residue ovine hypothalamic peptide that stimulates secretion of corticotropin and β-endorphin. Science 1981; 213: 1394-97.
66. Ebner K, Rupniak NM, Saria A, Singewal N. Substance P in the medial amygdala: Emotional stress-sensitive release and modulation of anxiety-related behavior in rats. Proc Natl Acad Sci USA 2004; 101(12): 4280-5.
67. Dunn AJ, Berridge CW. Physiological and behavioral responses to corticotropin-releasing factor administration: is CRF a mediator of anxiety or stress responses. Brain Res Rev 1990; 15: 71-100.
68. Wit RD, Herrstedt J, Rapoport B, et al. The oral NK1 antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebocontrolled phase III clinical trials. Eur J cancer 2004; 40(3): 403-10.
69. Sawchenko PE, Imaki T, Potter E, Kovacs K, Imaki J, Vale W. The functional neuroanatomy of corticotropin-releasing factor. Ciba Found Symp 1993; 172: 5-21.
70. An S, Cutler G, Zhao JJ, et al. Identification and characterization of a melaninconcentratinghormone receptor. Proc Natl Acad Sci USA 2001; 98(13): 7576-81.
71. Basso AM, Bratcher NA, Gallagher KB, et al. Lack of efficacy of melanin-concentrating hormone-1 receptor antagonists in models of depression and anxiety. Eur J Pharmacol 2006; 450 (1): 115-20.
72. Chaki S, Ogawab S, Toda Y, Funakoshi T, Okuyama S. Involvement of the melanocortin MC4 receptor in stress-related behavior in rodents. Eur J Pharmacol 2003; 474(1): 95-101.
73. Chaki S, Kanuma K. Neuropeptide receptors: Novel therapeutic targets for depression and anxiety disorders. Drugs Fut 2007; 32(9):809.
74. Jard S, Gaillard RC, Guillon G, Marie J, Schoenenberg P, Muller AF. Vasopressin as a target for antidepressant development: an assessment of the available evidence. Mol Pharmacol 1986; 30: 171-7.
75. Birnbaumer M. Vasopressin receptors. Trends Endocrinol Metab 2000; 11: 406-10.
76. Engelmann M, Wotjak CT, Neumann I, Ludwig M, Landgraf R. Behvioral and consequences of intracerebral vasopressin and oxytocin: focus on learning and memory. Neurosci Biobehav Rev 1996; 20: 341-58.
77. Griebel G, Simiand J, Wagnon J, et al. Anxiolytic and antidepressant- like effects of the non peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress related disorders. Proc Natl Acad Sci 2002; 99: 6370-375.
78. Jutkiewicz EM, Baladi MG, Folk JE, Rice KC, Woods JH. The δ- opioid receptor agonist SNC80 [(+)-4- [α(R)-α-[(2S,5R)-4-allyl- 2,5-dimethyl-1-piperazinyl]-(3-methoxybenzyl)-N,N-diethylbenzamide] synergistically enhances the locomotor-activating effects of some psychomotor stimulants, but not direct dopamine agonists, in rats. JPET 2008; 324(2): 714-724.
79. Williamson EM, Evans FJ. Cannabinoids in clinical practice. Drugs 2000; 60: 303-14.
80. Robson P. Therapeutics aspects of cannabis and cannabinoids. Br J Psychiatry 2001; 178: 107-15.
81. Martin M, Ledent C, Parmentier M, Maldonado R, Valverde O. Involvement of CB1 cannabinoid receptors in emotional behavior. Psychopharmacology 2002; 159: 379-87.
82. Corcos M, Guilbaud O, Hjalmarsson L, Chambry J, Jeammet P. Cytokines and depression: an analogic approach. Biomed Pharmacother 2002; 56(2): 105-10.
83. Tsigos C. Hypothalamic-pituitary-adrenal axis, neuroendocrine factors and stress. J Psychosomc Res 2002; 53 (4): 865-71.
84. Kenakin T. Inverse, protean, and ligand-selective agonism: matters of receptor conformation. FASEB J 2001; 15: 598-611.
85. Mantovani M, Pertile R, Santos ARS. Melatonin exerts an antidepressant like effect in the tail suspension test in mice evidence for involvement of N-methyl-D-aspartate receptors and the L-arginine nitric oxide pathway. Neurosci Lett 2003; 343: 1.
86. Kennedy SH. Agomelatine: efficacy at each phase of antidepressant treatment. CNS Drugs 2009; 23(2): 41-47.
87. Bares M, Novak T, Kopecek M, Stopkova P, Sos P. Is combined treatment more effective than switching to monotherapy in patients with resistant depression? A retrospective study. Neuro Endocrinol Lett 2009; 30(6): 723-8.
88. Nelson JC, Papakost GI. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry 2009; 166: 980-991.
89. Maxwell RA. Second generation antidepressants: The pharmacological and clinical significance of selected examples. Drug Develop Res 1983; 3(3): 203-11.
90. Mental Health Medications Available from: http: //www.nimh.nih.gov/health/publications/mental-healthmedications/ complete-index.shtml
91. Hage WE, Surguladze SA. Emerging treatments in the management of bipolar disorder - focus on risperidone long acting injection. Neuropsychiatr Dis Treat 2010; 6: 455-464.
92. Gelenberg AJ, Thase ME, Meyer RE, et al. The history and current state of antidepressant clinical trial design: a call to action for proof-of-concept studies. J Clin Psychiatry 2008; 69(10): 1513-28.
93. Guidance for industry Available from: www.fda.gov/downloads/ Drugs/.../Guidances/ucm071299.pdf
94. Moncrieff J. The antidepressant debate. Br J Psychiatry 2000; 180:193-94.